Search

CN-121971692-A - Wound surface treating agent and preparation method thereof

CN121971692ACN 121971692 ACN121971692 ACN 121971692ACN-121971692-A

Abstract

The application relates to a wound surface treating agent and a preparation method thereof, which relate to the technical field of medical appliances, and adopt polyvinylpyrrolidone (PVP) to carry out organic molecular inclusion and stabilization on chlorine dioxide, so that the chlorine dioxide can be kept in a dissolved state and chemical stability in a physiologically compatible weak alkaline solution, and can be directly used without acidic activation, thereby avoiding chemical stimulation of acid to a wound surface. When contacting wound exudates, the stabilizing system can gradually release chlorine dioxide molecules with strong oxidation activity under the action of body fluid ion environment, and plays a broad-spectrum and efficient antibacterial role on the wound surface locally. At the same time, the released chlorine dioxide can promote the local coagulation process by oxidation and contribute to the healing process. On the basis, the comprehensive performance of the composition is further enhanced through formulation design, the effects of rapidly converging wounds, reducing infection and promoting healing are realized, and the composition is simultaneously suitable for nursing skin wound surfaces with different characteristics.

Inventors

  • LIANG YANNIAN

Assignees

  • 北京鑫源恒信医疗器械有限公司

Dates

Publication Date
20260505
Application Date
20260323

Claims (7)

  1. 1. The wound surface treating agent is characterized by comprising an organic stable chlorine dioxide solution prepared by the following method: Continuously introducing chlorine dioxide gas into a purified water solution containing polyvinylpyrrolidone K-30 with the concentration of 2-4wt% at the temperature of 50-60 ℃ until the concentration of chlorine dioxide in the solution reaches 145-175 ppm to form a stable compound solution with chlorine dioxide molecules and polyvinylpyrrolidone combined through covalent bonds; And regulating the pH value of the stable compound solution to 7.0-9.0 to obtain the organic stable chlorine dioxide solution.
  2. 2. A wound treatment agent according to claim 1, wherein the wound treatment agent is in the form of a gel comprising magnesium aluminium silicate and an organic stabilised chlorine dioxide solution.
  3. 3. A wound treatment according to claim 2, wherein the gel-form wound treatment further comprises zinc acetate.
  4. 4. A wound treatment agent according to claim 1, wherein the wound treatment agent is in the form of a solution, and the solution further comprises aloe vera lyophilized powder.
  5. 5. A wound treatment agent according to claim 4, wherein the solution-based wound treatment agent further comprises zinc acetate.
  6. 6. A wound treatment agent according to claim 4 wherein the solution wound treatment agent is stored in a binary packaging container wherein the organic stabilized chlorine dioxide solution is stored separately from the other components.
  7. 7. A method of preparing a wound treatment according to any one of claims 1 to 7, comprising the steps of: S1, preparing a stable compound solution, namely, reacting sodium chlorite with citric acid in a reaction device to generate chlorine dioxide gas, continuously introducing the generated chlorine dioxide gas into a reactor containing a purified water solution, wherein the temperature of the purified water solution is maintained at 50-60 ℃, polyvinylpyrrolidone K-30 with the concentration of 3 percent is dissolved in the purified water solution, continuously ventilating and monitoring until the concentration of chlorine dioxide in the solution obtained in the reactor reaches 160+/-15 ppm, and stopping ventilation to obtain the stable compound solution; s2, preparing an organic stable chlorine dioxide solution, namely adjusting the pH value of the stable compound solution obtained in the step S1 to 7.0-9.0 by using a sodium hydroxide solution to obtain the organic stable chlorine dioxide solution; If the gel form is prepared, executing a step S3a, namely adding magnesium aluminum silicate into the organic stable chlorine dioxide solution obtained in the step S2, uniformly stirring until the system is completely hydrated to obtain a gel matrix; If a solution dosage form is prepared, executing the step S3b or S3c; s3b, adding aloe vera freeze-dried powder and zinc acetate into the organic stable chlorine dioxide solution obtained in the step S2, and stirring until the aloe vera freeze-dried powder and the zinc acetate are completely dissolved or uniformly dispersed to obtain a solution product, thereby obtaining a solution type wound surface treating agent; And S3c, respectively placing the organic stable chlorine dioxide solution obtained in the step S2, the aloe vera freeze-dried powder and the zinc acetate into different chambers of a binary packaging container to obtain the solution type wound surface treating agent.

Description

Wound surface treating agent and preparation method thereof Technical Field The application relates to the technical field of medical instruments, in particular to a wound surface treating agent and a preparation method thereof. Background Wound surface treatment is a fundamental and key link in clinical medicine and daily health care. Effective wound treatment agents are critical for preventing infection, controlling bleeding, promoting tissue regeneration, and reducing scarring. According to statistics, the number of deaths and complications caused by various wounds is high in the global scope, and the urgent clinical demands for developing efficient and safe wound care products are highlighted. The ideal wound surface treating agent has multiple functions of broad-spectrum antibiosis, rapid hemostasis, healing promotion, convenient use and the like, so as to cope with complex and diverse wound surface environments. At present, wound treatment agents on the market are mostly developed based on specific action mechanisms, and a plurality of main technical routes are formed. For example, one class of products has an antibiotic or chemically synthesized antibacterial agent (e.g., silver sulfadiazine, chlorhexidine) as a core component, focusing on anti-infection, but at risk of eliciting bacterial resistance or cytotoxicity. Another class of products employs bioactive materials, such as chitosan or derivatives thereof, primarily utilizing their natural hemostatic and film-forming properties, however their antimicrobial spectrum and efficacy in promoting healing are often limited. In addition, some products rely on growth factors (such as epidermal growth factor) or cytokines to directly stimulate tissue repair, but the products are often high in cost, poor in stability and single in function, and are difficult to independently cope with early infection and exudation of wound surfaces. Most of the prior art focuses on the intervention of a single pathological link, and when dealing with complex wound surfaces, a plurality of products are often required to be matched for use or dressing replacement is frequently carried out, so that the treatment cost and the operation complexity are increased, and additional pain can be brought to patients. Thus, there is a need in the art for a comprehensive wound treatment agent that reduces infection, hemostasis and healing multiple efficacy in one. In particular, developing a convenient treatment agent which has no need of harsh activation conditions, is mild to wound tissues, can be suitable for wound surfaces with different depths and areas, and becomes an important direction of current research. Disclosure of Invention The application provides a wound surface treating agent and a preparation method thereof, which have the effects of stopping bleeding, resisting infection and promoting wound surface healing, and simultaneously, the wound surface treating agent is convenient to use and can meet medical and daily requirements. In a first aspect, the present application provides a wound treatment agent, which adopts the following technical scheme: A wound treatment agent comprising an organic stabilized chlorine dioxide solution prepared by: Continuously introducing chlorine dioxide gas into a purified water solution containing polyvinylpyrrolidone K-30 with the concentration of 2-4wt% at the temperature of 50-60 ℃ until the concentration of chlorine dioxide in the solution reaches 145-175 ppm to form a stable compound solution with chlorine dioxide molecules and polyvinylpyrrolidone combined through covalent bonds; And regulating the pH value of the stable compound solution to 7.0-9.0 to obtain the organic stable chlorine dioxide solution. By adopting the technical scheme, the chlorine dioxide gas is introduced into the solution containing 3% polyvinylpyrrolidone K-30 (PVP) at 50-60 ℃, so that the stable compound solution with the closely combined chlorine dioxide and PVP molecules is directly prepared, and the chlorine dioxide is ensured to be effectively captured in a molecular state which can exist stably. And a stable chlorine dioxide system which can be directly used for wound surfaces without an additional acidic activator is successfully constructed. When the solution contacts exudates rich in proteins and electrolytes of wound surfaces, the solution can be mildly and controllably activated based on environmental changes, and continuously releases chlorine dioxide molecules with broad-spectrum efficient sterilization, so that an instant and strong anti-infection effect is realized, and chemical stimulation and secondary damage to new tissues caused by activation of exogenous acid are avoided. In addition, the pH value of the organic stable chlorine dioxide solution is regulated to be in the neutral to weak alkaline range of 7.0-9.0, so that the organic stable chlorine dioxide solution is more compatible with the physiological environment of a human body, the use sa